Dual therapy, consisting of a non-vitamin K oral anticoagulant combined with a single P2Y12 inhibitor, consistently demonstrated a reduction in bleeding complications compared to conventional triple therapy without compromising protection against ischemic events such as myocardial infarction, stroke, or stent thrombosis. Here, P2RY12 is linked to stroke disorder.